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Objective. Helicobacter pylori provokes a host of immune alterations upon colonizing the gastric mucosa. Design. We report 22
individuals with confirmed Helicobacter pylori infection who were also managed for the concurrent elevation of immunoglobulin
free light chain (kappa and lambda) levels. Result. Of the 22 patients, 15 patients (68.2%) had elevated free light chain levels: 6 patients
(40%) had only kappa chain elevation, 2 patients (13.3%) had only lambda chain elevation, and 7 patients (46.7%) had both kappa
and lambda chain elevation. Twenty out of the 22 patients (90.9%) were microbiologically confirmed cured with 3 patients being
lost to follow-up for repeat levels. Of the 3 patients who were lost to follow-up, 1 patient had only kappa chain elevation, 1 patient
had only lambda chain elevation, and 1 patient had both kappa and lambda chain elevation. For those who were cured (19 patients),
5 patients with kappa elevation had normalized values, 4 patients with lambda elevation had normalized values, and 2 patients with
combined kappa and lambda elevation had normalized values. For 6 out of the 19 patients, the light chain levels remained elevated.
Conclusion. We speculate that the Helicobacter pylori infection disrupts the immunoglobulin system with potential implications
being discussed below.

1. Introduction
Helicobacter pylori is one of the most pervasive bacterial
pathogens worldwide and is associated with an increased
risk of gastritis, gastric and duodenal ulcers, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue
(MALT) lymphoma [1, 2]. Indeed, it has been nearly three
decades since the Australian physicians Warren and Marshall
first isolated the pathogen and elucidated its association
with gastric and duodenal ulcers as well as gastritis, leading to significant research towards the treatment of these
gastrointestinal disorders [3]. While the incidence of the
H. pylori infection varies largely by socioeconomic status,
geographic region, age, and race, approximately one-half of
the world’s population has been estimated to be infected, with
the prevalence ranging from 30 to 40 percent in the United
States [4, 5]. In fact, in the United States, the prevalence
increases from less than 20% at 20 years of age to nearly 50%
at 50 years of age [6]. Today, with the advent of the newer

concomitant quadruple therapy, the eradication of H. pylori
has experienced success rates greater than 90 percent [7, 8].
In a patient with light chain deposition disease, a transient
increase in light chain levels was observed upon H. pylori
infection; while levels did not normalize after microbiological
cure, they down trended and returned to the patient’s baseline. The aforementioned phenomenon led us to evaluate if
there was in fact a disruption in the immunoglobulin system,
specifically in regards to free light chains, that accompanies
the Helicobacter pylori infection (J. Girón, personal observation).

2. Methods
In total, twenty-two adult patients—7 female patients and 15
male patients—who were diagnosed and selected randomly
with H. pylori disease from 2009 to 2011, confirmed by
a positive stool antigen test via an enzyme immunoassay
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Table 1: Patient demographics.

Characteristic
Total patients
Sex, %
Men
Women
Age (mean), years
Age (range), years
Confirmed H. Pylori microbiologic cure∗ , %

Table 2: Comorbid conditions.
Result
22
68.2
31.8
51.9
30–85
90.9%

∗

A microbiological cure was confirmed by a positive stool antigen test via
an enzyme immunoassay by the laboratories at Quest or LabCorp.

(Quest or LabCorp), had a quantitative evaluation of free
kappa and lambda light chain levels in serum (Table 1). The
noninvasive H. pylori stool antigen test that was utilized
has an overall sensitivity of 91% and specificity of 93% [9].
All of the patients were subject to a thorough history and
clinical examination in addition to a complete laboratory
investigation to determine their H. pylori status as well as the
presence of other potential infectious diseases.
The patients typically received a 7-to-10 day oral regimen
of clarithromycin, metronidazole, omeprazole, and bismuth
subsalicylate (Table 3). All of the patients with hepatitis C,
except patient 19, received Helicobacter pylori treatment prior
to the institution of treatment for hepatitis C. Thus, changes
in light chain levels were recorded before the patients were
treated for hepatitis C. Patient 19 received treatment for
strongyloidiasis but did not adhere to treatment for H. pylori
or hepatitis C (Table 4(c)). Confirmation of a microbiological
cure of the H. pylori infection with a repeat stool antigen
test was performed along with a repeat measurement of
the free light chain levels if previously elevated. All patients
were informed of the additional blood testing. Confirmatory
testing was performed from 3 weeks to 130 weeks after the
completion of treatment. The associated comorbid conditions
were also recorded (Table 2).

3. Results
The study included 22 patients with ages ranging from 30
to 85 years (mean of 51.9 years of age) (Table 1). Fifteen
patients had confirmed H. pylori disease and elevated light
chain levels. For 6 out of 15 patients (40%), only elevated
free kappa light chain levels were found, and for 2 out of 15
patients (13.3%), only elevated free lambda light chain levels
were found. For 7 out of 15 patients (46.7%), both kappa and
lambda light chain elevation was found. Overall, 15 out of
the 22 patients (68.2%) had an elevation in free kappa and/or
lambda light chain levels (Tables 2 and 3), while 7 patients
(31.8%) had normal lambda and kappa light chain levels.
Twenty of the twenty-two patients (90.9%) were confirmed microbiologically cured of the H. pylori infection
as evidenced by a repeat stool antigen test (Table 1). Three
patients (13.6%) failed to follow-up in an outpatient setting
to repeat free light chain values. Out of the 3 patients who
were lost to follow-up for repeat light chain values, 1 patient

Diseases
Acquired immunodeficiency syndrome
Chlamydia pneumonia
Coronary artery disease
Erythema nodosum
Erythrasma
Glucose-6-phosphate dehydrogenase deficiency
Hepatitis B
Hepatitis C
Human immunodeficiency virus
Human T-lymphotropic virus-I/II
Hyperlipidemia
Hypertension
Idiopathic CD4+ lymphocytopenia
Methicillin-resistant Staphylococcus aureus
Polymyalgia rheumatic
Sarcoidosis
Schistosomiasis
Strongyloides stercoralis
Treponema pallidum
Type 2 diabetes mellitus

Count
4
2
1
1
1
1
3
7
2
1
1
3
1
1
1
1
1
4
2
3

Table 3: Treatment regimen for H. Pylori patients.
Regimen
Clarithromycin 500 mg po bid, metronidazole 500 mg
po tid, omeprazole 20 mg po qid, and bismuth
subsalicylate 1 tbsp tid
Tetracycline 500 mg po qid, metronidazole 250 mg po
tid, omeprazole 20 mg po bid, and bismuth
subsalicylate 1 tbsp tid
Tetracycline 500 mg po qid, amoxicillin 500 mg po tid,
omeprazole 20 mg po bid, and bismuth subsalicylate
1 tbsp tid
Tetracycline 500 mg po qid, clarithromycin 500 mg po
bid, omeprazole 20 mg po bid, and bismuth
subsalicylate 1 tbsp tid
Clarithromycin 500 mg po bid, metronidazole 500 mg
po tid, lansoprazole 20 mg po bid, and bismuth
subsalicylate 1 tbsp tid
Clarithromycin 500 mg po bid, amoxicillin 500 mg po
tid, lansoprazole 20 mg po bid, and bismuth
subsalicylate 1 tbsp tid

Count
15

2

1

1

1

1

All regimens initially lasted between 7 and 10 days. Two of the patients were
retreated multiple times.

had only kappa chain elevation, 1 patient had only lambda
chain elevation, and 1 patient had both kappa and lambda
chain elevation.
We had 15 patients with confirmed H. pylori eradication
and abnormal light chain levels. Light chain levels were
monitored over a period of 3 to 130 weeks. Of these 15
patients, 3 patients were lost to follow-up (Table 4(d)). Three
patients with solitary kappa light chain elevation experienced

49
52
57
59

4
5
6
7

42

50

52

54

55

9

10

11

12

13

Male

Female

Male

Male

Male

Hepatitis B
None
Human immunodeficiency virus, Strongyloides
stercoralis, Treponema pallidum
Hepatitis C
Hepatitis B
Hepatitis C
Strongyloides stercoralis, Schistosomiasis

Comorbid diseases

6.3
11.1
20.7
14.1

10.3

Time for confirmation of
microbiological cure (weeks)
8.1
4.9

Hepatitis B
Acquired immunodeficiency
syndrome, human
T-lymphotropic virus-I/II,
erythrasma
Hepatitis C
Methicillin-resistant
Staphylococcus aureus, type 2
diabetes mellitus
Sarcoidosis, idiopathic CD4+
lymphocytopenia, erythema
nodosum, hypertension
Treponema pallidum, type 2
diabetes mellitus,
hyperlipidemia, hypertension

Comorbid diseases

12.6

4.7

129.4

4.6

14

Time for
confirmation of
microbiological
Cure (weeks)
2

22.1 (A)

28.7 (A)

271 (A)

19.7 (A)

19.1 (N)

20.2 (A)

Initial 𝜅
value
(mg/L)

17.9 (N)

15.2 (N)

17.4 (N)

16.02 (N)

10 (N)

16.78 (N)

Final 𝜅
value
(mg/L)

Yes

Yes

Yes

Yes

N/A

Yes

Normalization
of 𝜅 value

22.1 (N)

23.6 (N)

168 (A)

31.2 (A)

27.5 (A)

15.53 (N)

Initial 𝜆
value
(mg/L)

(b) Patients with elevated kappa and/or lambda light chain levels who experienced normalization of values

Male
Female
Male
Female

Male

Female
Female

Sex

19.6 (N)

20.9 (N)

16.9 (N)

24.2 (N)

16.5 (N)

14.91 (N)

Final 𝜆
value
(mg/L)

N/A

N/A

Yes

Yes

Yes

N/A

12.6

4.7

129.4

3.1

23.6

Time span between
initial and final
light chain value
(weeks)
5

14.4 (N)
24.7 (N)
16.2 (N)
12.6 (N)

12.36 (N)

13.3 (N)
12.9 (N)

Initial 𝜆 value (mg/L)

Normalization
of 𝜆 value

10.6 (N)
17 (N)
15.2 (N)
11.7 (N)

15.23 (N)

13.8 (N)
11.7 (N)

Initial 𝜅 value (mg/L)

Patient 8 has a chronic carrier state of hepatitis B surface antigen and a negative viral load. This patient has not received treatment for hepatitis B.
Patient 9 is on HIV medications and had light chain values normalized with H. pylori treatment.
Patient 10 received treatment for H. pylori prior to institution of hepatitis C treatment.
Patient 11 had a methicillin-resistant Staphylococcus aureus infection treated with persistently elevated light chain levels that are subsequently normalized after treatment of H. pylori.
Patient 13 received treatment for H. pylori prior to institution of syphilis treatment.

32

8

Female

48

3

Sex

30
43

1
2

Patient Age

Age

Patient

(a) Patients with initial normal kappa and lambda light chain levels

Table 4: Tracking free kappa and lambda light chain values in H. pylori patients.
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Male

47

52

64

51

54

71

14

15

16

17

18

19

Acquired immunodeficiency
syndrome
Hepatitis C, Chlamydia
pneumoniae
Hepatitis C
Acquired immunodeficiency
syndrome, glucose-6-phosphate
dehydrogenase deficiency,
Strongyloides stercoralis
Hepatitis C, hypertension
Hepatitis C, Strongyloides
stercoralis, type 2 diabetes
mellitus

Comorbid diseases

4.3

10.7

34.3

11.7

10.6

5.9

25.5 (A)

21.43 (A)

24 (A)

22.9 (A)

30.22 (A)

34.4 (A)

Initial 𝜅
value
(mg/L)

29.1 (A)

41.74 (A)

20.8 (A)

23.1 (A)

44.74 (A)

43 (A)

Final 𝜅
value
(mg/L)

Male

46

48

85

20

21

22

Male

Male

Sex

Patient Age

Chlamydia pneumoniae, human
immunodeficiency virus
Acquired immunodeficiency
syndrome
Polymyalgia rheumatica,
coronary artery disease

Comorbid diseases

No

No

No

No

No

No

Normalization
of 𝜅 value

Unknown

Unknown

8.1

Time for
confirmation of
microbiological
cure (weeks)

25.2 (A)

18 (N)

340 (A)

Initial 𝜅
value
(mg/L)

Not
measured
Not
measured
Not
measured

Final 𝜅
value
(mg/L)

N/A

N/A

N/A

Normalization
of 𝜅 value

(d) Patients who were lost to follow-up for repeat light chain values

Patients 15, 16, and 18 who have hepatic C received treatment for H. pylori prior to initiation of hepatitis C treatment.
Patient 19 did not receive treatment for H. pylori and is awaiting further workup for hepatitis C.

Male

Male

Male

Female

Male

Sex

Patient Age

Time for
confirmation of
microbiological
cure (weeks)

25.6 (N)

29.55 (A)

195 (A)

Initial 𝜆
value
(mg/L)

20.7 (N)

31.26 (A)

30 (A)

12.3 (N)

26.73 (A)

49.2 (A)

Initial 𝜆
value
(mg/L)

Not
measured
Not
measured
Not
measured

Final 𝜆
value
(mg/L)

21.1 (N)

71.23 (A)

23.6 (N)

11.7 (N)

27.07 (A)

56.2 (A)

Final 𝜆
value
(mg/L)

(c) Patients with elevated kappa and/or lambda light chain levels who experienced persistent elevation of values

N/A

N/A

N/A

Normalization
of 𝜆 value

N/A

No

Yes

N/A

No

No

Normalization
of 𝜆 value

N/A

N/A

N/A

Time span between
initial and final
light chain value
(weeks)

2.7

11.7

51.3

4.3

7.1

5.1

Time span between
initial and final
light chain value
(weeks)
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normalization of levels. One patient with solitary lambda
light chain elevation experienced normalization of levels.
Finally, 2 patients with combined kappa and lambda light
chain elevation experienced normalization of both levels
(Tables 4(a), 4(b), and 4(c)). The remaining 6 patients had
persistent elevation of kappa and/or lambda light chain levels
after successful eradication of H. pylori (Table 4(c)).
We had 7 patients with hepatitis C and H. pylori infection.
In 5 patients tested for cryoglobulins, all 5 were negative.

4. Discussion
To our knowledge, this is the first observation of an association between Helicobacter pylori infection and an elevation
of immunoglobulin free light chains. We found that 15 out of
22 patients (68.2%) had at least one light chain elevated at the
time of H. pylori diagnosis, while 7 out of 22 (31.8%) patients
had no disturbance in light chain levels. Our study has not
investigated the cause of this phenomenon. We speculate
that either unique bacterial strain factors, a host genetic
difference among patients, or a combination of both might
account for our observations. Some strains of H. pylori have
been identified as having low virulence and fail to incite
any gastroduodenal disease. Certain hosts carry a particular
HLA-DQA gene which induces a potent H. pylori antibodies
and T-cell response [10–13]. Our findings raise the possibility
of stratifying H. pylori patients into those with abnormal light
chain levels and those with normal levels. Long term followup of patients with persistent elevation of light chain levels
may lead to a better understanding of the biologic processes
involved.
A few reports of Russell body gastritis in H. pylori patients
show light chain deposits in the tissues of the gastric mucosa
and raise an intriguing notion as to a possible unique immunologic defense mechanism or immune disruption occurring
in H. pylori infected tissue [14–16]. For example, while H.
pylori’s urease activity is vital for its survival, an enhanced
immunological response to the enzyme may decrease the
bacteria’s persistence and sequelae [17]. The gene products of
cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA) are associated with a robust production of
cytokines and tissue inflammation [18, 19]. The presence or
absence of the aforementioned proteins assists in classifying
the distinct strains of H. pylori as well as providing further
information as to its association with disease [20]. The
virulent cag pathogenicity island (PAI), which encodes the
bacterial oncoprotein CagA, has been strongly linked to
carcinogenesis and is found in nearly 70% of H. pylori strains
worldwide [21, 22]. The connection between H. pylori and
disease may lie in the epigenetic control of gene expression as
the CagA protein not only interferes with the host’s cytoskeleton and cell-signaling pathways but also reduces levels of
p53 expression and increases the persistence of damaged
DNA [23, 24]. Furthermore, the CagA protein has been
shown to disrupt typical epithelial differentiation similar to
the process of epithelial-to-mesenchymal transition (EMT)
and is thought to play a role in tumorigenesis [25]. Thus, it
has been theorized that gastric carcinomas can be mediated
by Helicobacter pylori’s dynamic inflammatory effects on
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the p53 tumor suppressor gene, which has been found in
38–71% of gastric neoplasms [26, 27]. Certainly, further
investigation of the gastric and intestinal flora along with
the epigenetic influence of cagPAI may provide insight into
how Helicobacter pylori is influenced by its gastrointestinal
environment and can incite immune-mediated disease in
patients [28].
Terrier et al. (2009) have reported elevated immunoglobulin light chain levels in patients with hepatitis C infection
and mixed cryoglobulinemia [29]. In this series, 5 of the 7
patients with hepatitis C in whom cryoglobulin levels were
tested had negative values, suggesting that the elevation of
light chain levels was not associated with cryoglobulinemia.
Except patient 19, all of the patients with hepatitis C
and Helicobacter pylori coinfection received treatment for H.
pylori prior to the initiation of hepatitis C therapy. Patient
19 failed to take the H. pylori medication and has not
been treated for hepatitis C. In patient 10, normalization
of light chain levels after H. pylori treatment and prior to
initiation of hepatitis C treatment suggests that the initial
light chain elevation was a result of the H. pylori infection. The
persistence of elevated light chain levels in patients 15, 16, and
18 after H. pylori treatment and before hepatitis C treatment
raises the possibility that hepatitis C may have contributed
to this immune disturbance. Further studies will need to be
conducted to further investigate this issue.
The persistence of light chain elevation in 6 out of the 19
patients suggests an ongoing stimulus of the immunoglobulin
system which might be the result of either a coinfection with
hepatitis C or another comorbid process. Alternatively, in the
individuals with persistently elevated light chain levels, the
prior infection with Helicobacter pylori may have initiated the
early stage of a light chain immunoglobulin dysfunction. This
potential immunoglobulin system dysfunction may represent
the first stage in the development of a monoclonal gammopathy of unknown significance (MGUS), as the stomach,
intestines, and associated lymphoid tissues constitute the
largest immune organ in the human body, such a hypothesis
is worth exploring.

5. Summary
(1) What is already known about this subject is as follows.
(i) The prevalence of H. pylori ranges from 30 to 40 percent in the United States.
(ii) H. pylori is associated with gastric and duodenal
ulcers, gastric adenocarcinoma, and MALT lymphoma.
(iii) Reports of Russell body gastritis in H. pylori patients
show light chain deposits.
(2) The new findings are as follows.
(i) This is the first observation of association between
Helicobacter pylori and an elevation of immunoglobulin free light chains.
(ii) 15/22 patients (68.2%) had at least one light chain
elevated during H. pylori diagnosis.
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(iii) Persistence of light chain elevation in 6/19 patients
(31.6%) suggests ongoing stimulus of immunoglobulin system.

(3) How it might impact on clinical practice in forseeable
future is as follows:
(i) give possibility of stratifying H. pylori patients into
those with abnormal light chain levels and those with
normal levels;
(ii) allow clinicians to track patients with persistently elevated light chain levels in what may represent the first
stage in the development of a monoclonal gammopathy of unknown significance (MGUS);
(iii) suggest long term follow-up on patients with persistent elevation of light chain levels for a better understanding of the biologic processes involved.
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